

Supplementary Table 1: Patient characteristics of Ty21a-treated patients

Characteristics	Phase Ia (A) 1 x 10 ⁸ CFU ^a	Phase Ib (F) 5 x 10 ⁸ CFU ^a	Total
Number of patients	3	10	13
Age, yr, median (IQR)	76 (71-79)	74 (58-75)	74 (61-76)
Sex, n			
Male	3	9	12
Female	0	1	1
Number of tumors, n			
Single	2	4	6
2-7	1	6	7
> 8	0	0	0
Tumor diameter, n			
< 3 cm	3	9	12
> 3 cm	0	1	1
Prior recurrence,			
Primary	2	5	7
< 1 recurrence/yr	1	2	3
> 1 recurrence/yr	0	3	3
Category and grade, n			
Ta low grade	3	10	13
Ta high grade	0	0	0
T1 high grade	0	0	0
Any CIS positive	0	0	0
Risk of recurrence^b, n			
Low	1	1	2
Intermediate	2	9	11
High	0	0	0
Risk of progression^b, n			
Low	1	1	2
Intermediate	2	9	11
High	0	0	0

^a Data from Lucca et al. Eur Urol Open Sci. 2022 Oct 3;45:55-58.

^b according to EORTC score

CIS = Carcinoma In Situ; IQR: Interquartile Range